United States Drug Patent 9,254,286: Claim Scope, Zerviate Exclusivity, and Cetirizine Ophthalmic Patent Landscape

U.S. Patent No. 9,254,286 is a formulation patent directed to a topical ophthalmic cetirizine product. Its commercial relevance is tied to Zerviate, a 0.24% cetirizine ophthalmic solution approved by the FDA for ocular itching associated with allergic conjunctivitis. The strongest claim is claim 1, which requires a specific excipient system, near-neutral pH, and the absence of cyclodextrin or another solubilizing compound. The patent does not broadly cover every cetirizine eye drop.

The patent creates meaningful formulation barriers for a generic that seeks to reproduce Zerviate's composition. A competing product that changes the cetirizine concentration, removes or materially changes a listed excipient, uses a cyclodextrin, or moves outside the claimed pH range may avoid literal infringement. Such a product would still require FDA approval and could face infringement allegations under the doctrine of equivalents.

What does U.S. Patent 9,254,286 cover?

U.S. Patent 9,254,286 covers a topical ophthalmic formulation consisting essentially of:

Component	Claimed concentration
Cetirizine	0.24% w/v
Polyethylene glycol 400	1%
Dibasic sodium phosphate, anhydrous	0.2%
Hypromellose	0.25%
Polysorbate 80	0.1%
Glycerin	1.8%
Benzalkonium chloride	0.01%
Edetate disodium	0.025%
Purified water	Balance
pH	6.8 to 7.2
Excluded materials	Cyclodextrin or other solubilizing compound

The claim also permits cetirizine hydrochloride or cetirizine dihydrochloride under claim 2. Claim 3 identifies several dosage-form categories, including aqueous formulations, ointments, oils, suspensions, emulsions, and drug-delivery devices.

The commercial product Zerviate is an aqueous ophthalmic solution containing cetirizine hydrochloride at an equivalent cetirizine concentration of 0.24%. Its FDA-approved formulation includes the excipients identified in the patent claim, although the commercial label should control when comparing the marketed product with the claim language.[2]

How should claim 1 be interpreted?

Claim 1 is a narrow composition claim with a partially open transition phrase.

The effect of "consisting essentially of"

"Consisting essentially of" permits the presence of additional ingredients unless those ingredients materially alter the basic and novel characteristics of the claimed formulation. The formulation is not closed in the same manner as a claim using "consisting of," but it is narrower than a claim using "comprising."

The basic and novel characteristics likely include:

Delivery of cetirizine in a topical ophthalmic formulation.
Use of the specified excipient system.
Solubilization and stabilization without cyclodextrin or another solubilizing compound.
A pH between 6.8 and 7.2.
Suitability for ophthalmic administration.

An accused product containing an unlisted preservative, buffer, tonicity agent, or stabilizer would not automatically fall outside the claim. The relevant question would be whether the additional ingredient materially changes the formulation's basic and novel characteristics.

The significance of the concentration limitations

The claim recites discrete concentrations rather than broad ranges. It does not expressly state that the concentrations may vary by a percentage, such as plus or minus 10%. A generic formulation with 0.20% or 0.30% cetirizine would therefore present a stronger literal noninfringement position than a product matching 0.24%.

The same analysis applies to the excipients. A product containing 0.9% polyethylene glycol 400 instead of 1%, or 0.20% hypromellose instead of 0.25%, may avoid literal infringement depending on claim construction and the evidence concerning formulation tolerances.

In pharmaceutical manufacturing, assay specifications and batch variation do not necessarily eliminate infringement. Courts generally distinguish between the claimed formulation target and ordinary analytical variation around that target. A product intentionally designed outside the claimed concentration, with validated manufacturing specifications, presents a stronger design-around position.

The pH limitation

The pH requirement of 6.8 to 7.2 is an important narrowing limitation. A formulation at pH 6.5 or 7.5 would fall outside the express numerical range. A formulation at pH 7.0 would satisfy the limitation if the remaining elements were present.

The pH limitation also provides a practical design-around route. A generic sponsor could develop a formulation at a different pH, but it would need to establish stability, tolerability, preservative performance, cetirizine solubility, and bioequivalence or other applicable FDA requirements.

The no-cyclodextrin limitation

The claim expressly excludes cyclodextrin and other solubilizing compounds. This limitation is unusual because it defines the invention partly by what the formulation does not contain.

A product using hydroxypropyl-beta-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, or another compound principally used to increase cetirizine solubility would have a strong literal noninfringement argument. The same may apply to other ingredients that function primarily as solubilizers, although the legal analysis would depend on the ingredient's actual role and the claim construction record.

What is the scope of claim 2 for cetirizine salts?

Claim 2 expressly covers cetirizine hydrochloride and cetirizine dihydrochloride. The claim does not appear to expand to every possible cetirizine salt unless the parent claim's use of "cetirizine" is construed broadly enough to include the relevant salt form.

The salt limitation is commercially important because Zerviate uses cetirizine hydrochloride. A generic using the same active moiety in the same salt form would not obtain a design-around advantage from changing the nomenclature or crystalline form alone.

A substantially different salt, ester, prodrug, or active derivative would raise separate questions involving:

Whether it is legally "cetirizine" under the claim.
Whether it is pharmaceutically equivalent to the approved active ingredient.
Whether the FDA would treat it as the same active ingredient for an ANDA.
Whether it would infringe under the doctrine of equivalents.

How broad is claim 3 for dosage forms and delivery systems?

Claim 3 lists aqueous formulations, ointments, oils, suspensions, emulsions, and drug-delivery devices. On its face, this is broader than the marketed aqueous eye drop.

The dependency on claim 1, however, remains significant. Claim 3 does not remove the parent claim's concentration, excipient, pH, and no-solubilizer requirements. An ointment or oil would need to be reconciled with the requirement for purified water and the claimed excipient system.

This creates a potential claim-construction issue. Some listed dosage forms may be difficult to practice while retaining all limitations of claim 1. For example:

An oil-based formulation may not contain purified water in the same functional manner as an aqueous formulation.
A drug-delivery device may not have a conventional bulk pH.
An ointment may require different excipients and rheological properties.
A suspension may not have the same solubilization characteristics as a solution.

The claim should therefore be read as covering formulations within those categories that still satisfy every limitation inherited from claim 1. Claim 3 does not independently protect an unrestricted cetirizine ointment, oil, suspension, emulsion, or implant.

What patents protect Zerviate and cetirizine ophthalmic products?

U.S. Patent 9,254,286 is the principal patent associated with the specific Zerviate formulation. The patent's commercial value is concentrated in its composition claim rather than in a broad active-ingredient monopoly. Cetirizine itself is an established antihistamine, and the patent does not prevent competitors from developing unrelated ocular antihistamine products.

The relevant patent categories are:

Patent category	Relevance to Zerviate
Active ingredient patent	Limited, because cetirizine is an established compound
Composition patent	Core protection under U.S. 9,254,286
Method-of-use patent	May protect treatment of ocular itching or allergic conjunctivitis if separately listed and enforceable
Formulation patent	U.S. 9,254,286 protects the specified excipient and pH profile
Manufacturing patent	Could affect commercial manufacture if separate process claims exist
Device patent	Relevant only if a delivery device is separately claimed
Regulatory exclusivity	Separate from patent protection and generally shorter

The patent should not be treated as a complete monopoly over cetirizine ophthalmic therapy. Its practical scope depends on whether a competing product copies the claimed formulation or uses a materially equivalent formulation.

When does U.S. Patent 9,254,286 expire?

The patent has a reported expiration date of July 8, 2029, based on the patent family's earliest effective priority date and the standard patent-term framework.[1][3] The effective date should be checked against the USPTO patent term data and any applicable patent term adjustment, terminal disclaimer, or disclaimer recorded for the specific patent.

The principal commercial timeline is:

Event	Date or period
Earliest reported priority date	July 8, 2009
Patent issued	February 9, 2016
Zerviate FDA approval	May 18, 2017
Reported patent expiration	July 8, 2029
Expected post-expiration generic opportunity	Subject to FDA approval and any other enforceable rights

The remaining protection is composition-focused. Patent expiry does not guarantee immediate generic entry. An ANDA sponsor must still complete the applicable FDA pathway, resolve patent certifications, and address any separate listed patent or regulatory exclusivity.

What is the FDA regulatory and Orange Book status of Zerviate?

Zerviate was approved under NDA 210514 as a prescription ophthalmic solution containing cetirizine hydrochloride. The approved indication is the temporary prevention of ocular itching associated with allergic conjunctivitis.[2]

Cetirizine is an older active ingredient, so Zerviate did not receive the full five-year new chemical entity exclusivity associated with a first approval of a new active moiety. The product received a period of FDA regulatory exclusivity tied to new clinical investigations, generally three years from approval, subject to the statutory requirements and the FDA's listing records.[4]

The Orange Book is the controlling FDA source for listed patents and exclusivity. A patent listed for an NDA can require an ANDA applicant to submit a Paragraph IV certification if the applicant seeks approval before patent expiry. The relevant distinctions are:

Patent expiry controls the end of enforceable patent rights.
FDA exclusivity can block approval even when no patent prevents approval.
Orange Book listing controls the ANDA certification process.
A patent not listed in the Orange Book may still be enforceable against a marketed product, but it does not create the same ANDA certification mechanism.

U.S. Patent 9,254,286 is the key patent to examine in any Zerviate ANDA strategy. The Orange Book listing and current patent-use-code records should be reviewed as of the proposed filing date because FDA records can change through delisting, correction, or expiration.

What Paragraph IV challenges could target this patent?

An ANDA applicant seeking approval before the reported July 2029 expiration would generally need to address the listed patent through a certification. A Paragraph IV challenge would assert that the patent is invalid, unenforceable, or not infringed.

Likely noninfringement positions

A generic sponsor could argue that its product does not contain:

Exactly 0.24% cetirizine.
The complete claimed excipient system.
The 6.8 to 7.2 pH range.
The claimed absence of cyclodextrin or another solubilizing compound.
Cetirizine hydrochloride or dihydrochloride, if using a legally distinct active form.
A formulation falling within the dosage-form language of claim 3.

The most credible design-around route is a formulation that changes multiple limitations rather than making a minor adjustment to one excipient. For example, a product with a different cetirizine concentration, a different buffer system, and cyclodextrin-based solubilization would present a materially different formulation.

Likely validity positions

A Paragraph IV applicant could challenge validity based on:

Anticipation by an earlier cetirizine ophthalmic formulation.
Obviousness based on cetirizine's known antihistamine activity and conventional ophthalmic excipients.
Written-description or enablement issues involving the broad alternatives in claim 3.
Indefiniteness or claim-construction disputes concerning "other solubilizing compound."
Lack of a credible distinction between the claimed formulation and prior-art cetirizine preparations.

The patent holder would likely rely on the specific combination of concentration, excipient selection, pH, and cyclodextrin exclusion as the inventive feature. The strength of that response would depend on the patent's examples, comparative data, prosecution history, and the closest prior art.

What generic entry risks exist before 2029?

The generic entry risk is moderate rather than absolute. The composition claim is detailed, which improves the patent holder's position against a copycat formulation. The same detail gives a generic sponsor several design-around options.

Generic strategy	Patent risk	Commercial and regulatory risk
Copy the Zerviate formulation	High	Lower formulation-development risk, higher litigation risk
Change pH outside 6.8 to 7.2	Lower literal-infringement risk	Stability and tolerability must be demonstrated
Use cyclodextrin	Lower literal-infringement risk	New formulation and FDA comparability issues
Change multiple excipients	Lower	Potentially significant development burden
Use another antihistamine	No direct cetirizine claim risk	Competes as a different product
Use cetirizine in a different delivery device	Fact-specific	Device and formulation requirements may increase
Wait for patent expiry	Lowest patent risk	Delays market entry until 2029 or later

A product that copies the approved formulation creates the greatest exposure to a Paragraph IV suit and a potential 30-month stay under the Hatch-Waxman framework if statutory conditions are met. A product designed around the claim may avoid that risk but could require a 505(b)(2) application rather than an ANDA if the formulation or clinical profile is not sufficiently equivalent to the reference product.[5]

What patent litigation or settlement agreements affect Zerviate?

No widely reported, industry-defining settlement involving U.S. Patent 9,254,286 has established an earlier generic launch date for Zerviate. The principal litigation risk remains the potential enforcement of the formulation patent against an ANDA applicant that files a Paragraph IV certification.

A settlement could permit an authorized generic, a licensed generic, or a later launch before the nominal patent expiry. Such terms are not inferred from the patent itself. The relevant records would include district-court complaints, FDA Paragraph IV notices where publicly available, court docket entries, and any FTC-reviewed pharmaceutical patent settlement.

The absence of a publicly prominent settlement does not eliminate litigation risk. It means that the commercial entry date should be modeled from the patent expiration date unless a binding license, court judgment, or settlement provides a different date.

How strong is the patent estate for cetirizine ophthalmic treatment?

The estate is stronger against exact or near-exact copies than against broad therapeutic competition.

Strengths

The claim identifies a complete and commercially relevant formulation.
The claimed cetirizine concentration matches the marketed Zerviate product.
The pH range is specific and operationally measurable.
The claim excludes cyclodextrin and other solubilizing compounds, creating a clear formulation distinction.
The patent covers the active cetirizine salt used in the commercial product.

Weaknesses

The claim does not broadly cover all cetirizine ophthalmic formulations.
The numerical limitations may permit design-around development.
Claim 3 contains broad dosage-form alternatives that may create enablement and construction disputes.
Cetirizine's prior use as an antihistamine may support obviousness arguments.
A generic can pursue a different formulation or a different antihistamine.

The patent has meaningful blocking power for a same-formulation ANDA. It is less effective as a barrier to a technically differentiated ophthalmic antihistamine product.

How does Zerviate compare with competing ophthalmic antihistamines?

Zerviate competes with ophthalmic products containing olopatadine, ketotifen, alcaftadine, and bepotastine. Those products generally rely on separate active ingredients and separate patent families.

Product or active ingredient	Typical role in market	Relationship to U.S. 9,254,286
Zerviate, cetirizine	Ophthalmic antihistamine for ocular itching	Directly tied to the patent
Pataday, olopatadine	Ophthalmic antihistamine and mast-cell stabilizer	Separate active ingredient and patent estate
Zaditor/Alaway, ketotifen	OTC ophthalmic antihistamine	No direct cetirizine patent overlap
Lastacaft, alcaftadine	Ophthalmic antihistamine	Separate formulation and method-of-use rights
Bepreve, bepotastine	Prescription ophthalmic antihistamine	Separate active ingredient and patent estate

The patent does not prevent these competitors from marketing their products. Its competitive effect is concentrated on cetirizine-based copies.

What are the manufacturing and geographic IP barriers?

The patent is a U.S. right. It does not directly block manufacture, sale, or use outside the United States. Foreign equivalents, continuations, and national-stage filings must be assessed separately by jurisdiction.

Manufacturing risk is highest when a contract manufacturer uses the same target composition, process conditions, and quality specifications as the reference product. A process patent would create a separate infringement question, but the provided claims are composition claims. They do not expressly require a particular mixing sequence, sterilization process, filling method, or container-closure system.

The patent therefore creates less manufacturing-process protection than a dedicated process patent. Its main barrier is the composition supplied, sold, or used in the United States.

What is the revenue exposure from U.S. Patent 9,254,286?

Zerviate-specific revenue is not generally disclosed as a separately reported line item by its commercial owner. The exposure should therefore be modeled using product-level sales estimates, prescription volume, net price, payer mix, and the probability of an earlier generic launch.

The relevant commercial scenarios are:

Continued branded sales through patent expiry.
A Paragraph IV challenge followed by litigation.
A settlement allowing entry before July 2029.
A noninfringing generic formulation entering after FDA approval.
Competition from other ophthalmic antihistamines without a cetirizine generic.

The highest revenue risk would arise from an approved generic that copies the Zerviate formulation and launches after a successful challenge or settlement. A differentiated product may reduce patent exposure but could have a slower regulatory and commercial path.

Key Takeaways

U.S. Patent 9,254,286 is a narrow but commercially important formulation patent for cetirizine ophthalmic solution.
Claim 1 requires 0.24% cetirizine, a defined excipient system, pH 6.8 to 7.2, and no cyclodextrin or other solubilizing compound.
Claim 2 covers cetirizine hydrochloride and dihydrochloride.
Claim 3 lists broad dosage-form categories but remains subject to every limitation of claim 1.
The reported patent expiration date is July 8, 2029.
The patent is strongest against an exact Zerviate copy and weaker against a formulation that changes several claim elements.
Zerviate's FDA approval was May 18, 2017, under NDA 210514.
Cetirizine ophthalmic competitors using olopatadine, ketotifen, alcaftadine, or bepotastine do not directly infringe this patent.
A pre-expiry ANDA would likely require a patent certification, with Paragraph IV creating the principal litigation pathway.
Product-specific revenue exposure is not separately disclosed, so the commercial value depends on market share and the probability of an earlier generic launch.

FAQs About U.S. Patent 9,254,286

Can a generic use cetirizine at 0.24% and avoid this patent?

Not reliably if it also uses the claimed excipients, pH range, and absence of cyclodextrin or another solubilizer. Changing only one immaterial formulation parameter may not eliminate infringement risk.

Does the patent cover all cetirizine eye drops?

No. The patent claims a particular formulation architecture. A cetirizine ophthalmic product with a materially different concentration, excipient system, pH, or solubilization approach may fall outside the literal claim scope.

Is cyclodextrin a viable design-around for a Zerviate generic?

It may provide a strong literal noninfringement position because the claims expressly exclude cyclodextrin and other solubilizing compounds. The sponsor would still need to address formulation performance and the applicable FDA pathway.

Can a company market a cetirizine ophthalmic product outside the United States before 2029?

U.S. Patent 9,254,286 does not by itself control foreign markets. The company must assess patent family members and enforceable rights in each target jurisdiction.

Would a cetirizine suspension automatically avoid the patent?

No. Claim 3 expressly identifies suspensions, and a suspension could still infringe if it satisfies the inherited composition, concentration, pH, excipient, and exclusion limitations of claim 1.

References

United States Patent and Trademark Office. (2016). U.S. Patent No. 9,254,286, ophthalmic compositions comprising cetirizine.
U.S. Food and Drug Administration. (2017). Zerviate cetirizine hydrochloride ophthalmic solution prescribing information.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and Hatch-Waxman patent certification procedures.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harrow Eye	ZERVIATE	cetirizine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	208694-001	May 30, 2017		RX	Yes	Yes	9,254,286*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2755679	⤷ Start Trial
European Patent Office	2408453	⤷ Start Trial
European Patent Office	2547340	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,254,286

Which drugs does patent 9,254,286 protect, and when does it expire?

Summary for Patent: 9,254,286